Related to Roche Takes a Stab at Getting mAbs Under the Skin

• Genome Testing Reduces Overtreatment
  Study after study has shown that molecular diagnostics can help oncologists more effectively treat patients.
  
• 10 Predictions That Will Transform Healthcare
  Peer into GEN's crystal ball for a glimpse of what's to come.
  
• DNA Methylation Rules: Studying Epigenetics with New Tools
  The tools to unravel the epigenetic control mechanisms that influence how cells control access of transcriptional proteins to DNA are just beginning to emerge.
  
• DNA to Hang Your Hat On
  Scientists are coming up with amazing new uses for DNA origami.
  
• Women and Smoking
  Looking for a reason to quit, ladies? Look no further.
  
• Performing “Informative Clinical Trials” in Mice
  Patient-derived tumor xenografts: better than cancer cell lines for preclinical testing in animal models?
  
• Cancer Model Database Emerges from WOMB
  Oncology researchers wishing for a tool to help them find available models and services may have had their prayers answered.
  
• Detecting Acquired Drug Resistance in Cancer
  New methods allow noninvasive analysis in blood plasma.
  
• The Tumor Microenvironment as a Drug Target: Chasing Slippery Targets
  This first part of a two-part series discusses how researchers are looking at ways to attack tumors by targeting the cellular frameworks that keep them alive.
  
• The Tumor Microenvironment as a Drug Target, Part II
  In the search for new targets, cancer researchers are taking a closer look at the cellular support networks that allow tumors to survive.
  
• Literature Review: A Step Closer to Personalized Medicine
  Researchers use patient-specific cell lines derived in mice to personalize chemotherapy.
  
• Moving Genomics Closer to the Clinic
  Foundation Medicine and Memorial Sloan-Kettering Cancer Center are working to translate genomic information into personalized cancer treatment.
  
• Cancer’s Bitter Medicine
  CML experts raise industry hackles by decrying high-and-rising cost of treatments.
  
• GEN Exclusive: 2009 Laskers Honor Advances in Stem Cell Technology and Cancer Therapy
  Work cited will revolutionize cancer therapy and impact a potential $700 million global stem cell market.
  
• Antibody-Drug Conjugates to Fight Cancer
  While mAbs have been extremely successful, these empowered antibodies are touted as the next big blockbusters.
  
• Ocrelizumab: One Size Does Not Fit All
  Risk of serious infections has hampered mAb’s development in RA and LE, but drug is still being tested in MS.
  
• Avastin: Time for a Predictive Test
  Roche’s strategy to expand the use of Avastin into the first-line and adjuvant settings is particularly dependent on identifying those most likely to see a benefit.
  
• Weighing the Benefits of Rituximab Maintenance Therapy for FL
  Drug may be more cost-effective and improve PFS, but questions about overall survival remain.
  
• This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
  Among big news was Roche’s companion diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA’s Avastin decision.
  
• Literature Review: Which Drug Combination Will Unlock Triple-Negative Breast Cancer?
  Researchers describe a strategy for treating TNBC that combines noncompetitive antibodies to achieve degradation of EGFR and tumor inhibition.